Biomaterial-based local delivery of anti-inflammatory drugs, cytokines, and growth factors for bone regeneration
- 1Department of Orthopaedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
- 2Dalian Medical University, Dalian, China
Abstract
Large and biologically compromised bone defects remain difficult to repair because structural loss is often accompanied by persistent inflammation, insufficient vascularization, inadequate recruitment of reparative cells, and reduced osteogenic capacity. Biomaterial-based local delivery offers a means of addressing these interacting barriers by retaining therapeutic agents at the defect site, protecting labile bioactive molecules, and controlling the magnitude and duration of local exposure. This review adopts a barrier-oriented and exposure-centered framework that links the dominant biological deficit and stage of healing with therapeutic-agent selection, biomaterial-carrier properties, and local exposure design. We compare major therapeutic categories, scaffold platforms, and strategies for controlling release rate, timing, sequence, spatial distribution, and stimulus responsiveness. Across different bone-defect settings, regenerative performance depends less on maximizing cargo loading, prolonging release, or increasing material complexity than on matching dose, retention, bioactivity, and exposure profile to a defined therapeutic need. Key translational barriers include uncertain dose–exposure relationships, discrepancies between in vitro release and in vivo exposure, manufacturing and sterilization constraints, reproducibility, and limited clinical validation. Future development should prioritize biologically timed, quantitatively defined, reproducible, and clinically practical delivery systems.
Related
- Pro-Inflammatory Cytokines as Core Mediators of Colonic Epithelial Barrier Dysfunction: Roles of TNF-α, IFN-γ, IL-1β, and IL-6
- Ivermectin enhances the transcription of pro-inflammatory cytokines in equine leukocytes stimulated with LPS and nigericin.
- Differential Impacts of Platelet-Rich Plasma and Hyaluronic Acid on miR-132 Modulation, Inflammatory Cytokines (IL-1β and IL-6), and Functional Recovery in Knee Osteoarthritis: A Randomized Controlled Trial
- Impact of opioid-based versus opioid-free anaesthesia on postoperative recovery, circulating inflammatory cytokines and brain-derived neurotrophic factor.
- A transcriptomic atlas of macrophage polarization induced by inflammatory and reparative cytokines reveals cytokine-specific and synergistic polarization programs
BibTeX
@article{shi2026biomaterialbased,
title = {{Biomaterial-based local delivery of anti-inflammatory drugs, cytokines, and growth factors for bone regeneration}},
author = {Jiaming Shi and Jiaming Shi and Jiahe Liu and Zewen Wang and Haoqiang Wang and Haoqiang Wang and Zhaoyang Guo and Zhaoyang Guo and Baoyi Liu},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
month = oct,
doi = {10.3389/fbioe.2026.1996624},
url = {https://doi.org/10.3389/fbioe.2026.1996624},
note = {CC BY},
}
RIS
TY - JOUR
TI - Biomaterial-based local delivery of anti-inflammatory drugs, cytokines, and growth factors for bone regeneration
AU - Jiaming Shi
AU - Jiaming Shi
AU - Jiahe Liu
AU - Zewen Wang
AU - Haoqiang Wang
AU - Haoqiang Wang
AU - Zhaoyang Guo
AU - Zhaoyang Guo
AU - Baoyi Liu
PY - 2026
DA - 2026/10/23
JO - Frontiers in Bioengineering and Biotechnology
DO - 10.3389/fbioe.2026.1996624
UR - https://doi.org/10.3389/fbioe.2026.1996624
AB - Large and biologically compromised bone defects remain difficult to repair because structural loss is often accompanied by persistent inflammation, insufficient vascularization, inadequate recruitment of reparative cells, and reduced osteogenic capacity. Biomaterial-based local delivery offers a means of addressing these interacting barriers by retaining therapeutic agents at the defect site, protecting labile bioactive molecules, and controlling the magnitude and duration of local exposure. This review adopts a barrier-oriented and exposure-centered framework that links the dominant biological deficit and stage of healing with therapeutic-agent selection, biomaterial-carrier properties, and local exposure design. We compare major therapeutic categories, scaffold platforms, and strategies for controlling release rate, timing, sequence, spatial distribution, and stimulus responsiveness. Across different bone-defect settings, regenerative performance depends less on maximizing cargo loading, prolonging release, or increasing material complexity than on matching dose, retention, bioactivity, and exposure profile to a defined therapeutic need. Key translational barriers include uncertain dose–exposure relationships, discrepancies between in vitro release and in vivo exposure, manufacturing and sterilization constraints, reproducibility, and limited clinical validation. Future development should prioritize biologically timed, quantitatively defined, reproducible, and clinically practical delivery systems.
SN - 2296-4185
ER -